268 related articles for article (PubMed ID: 24490861)
1. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.
Wang Y; Parlevliet ET; Geerling JJ; van der Tuin SJ; Zhang H; Bieghs V; Jawad AH; Shiri-Sverdlov R; Bot I; de Jager SC; Havekes LM; Romijn JA; Willems van Dijk K; Rensen PC
Br J Pharmacol; 2014 Feb; 171(3):723-34. PubMed ID: 24490861
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice.
Parlevliet ET; Wang Y; Geerling JJ; Schröder-Van der Elst JP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H; Rensen PC
PLoS One; 2012; 7(11):e49152. PubMed ID: 23133675
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Arakawa M; Mita T; Azuma K; Ebato C; Goto H; Nomiyama T; Fujitani Y; Hirose T; Kawamori R; Watada H
Diabetes; 2010 Apr; 59(4):1030-7. PubMed ID: 20068138
[TBL] [Abstract][Full Text] [Related]
4. Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice.
Li Z; Wang Y; van der Sluis RJ; van der Hoorn JW; Princen HM; Van Eck M; Van Berkel TJ; Rensen PC; Hoekstra M
Biochem Pharmacol; 2012 Sep; 84(6):821-9. PubMed ID: 22750059
[TBL] [Abstract][Full Text] [Related]
5. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
[TBL] [Abstract][Full Text] [Related]
6. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.
Tashiro Y; Sato K; Watanabe T; Nohtomi K; Terasaki M; Nagashima M; Hirano T
Peptides; 2014 Apr; 54():19-26. PubMed ID: 24418070
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
Allam MM; El Gazzar WB
Arch Physiol Biochem; 2018 Feb; 124(1):10-17. PubMed ID: 28696785
[TBL] [Abstract][Full Text] [Related]
8. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages.
Bieghs V; Rensen PC; Hofker MH; Shiri-Sverdlov R
Atherosclerosis; 2012 Feb; 220(2):287-93. PubMed ID: 21930273
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide Lowers Cholesteryl Ester Transfer Protein by Activating F4/80
van der Tuin SJL; Li Z; Berbée JFP; Verkouter I; Ringnalda LE; Neele AE; van Klinken JB; Rensen SS; Fu J; de Winther MPJ; Groen AK; Rensen PCN; Willems van Dijk K; Wang Y
J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29525783
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
11. Fucoidan alleviates high-fat diet-induced dyslipidemia and atherosclerosis in ApoE(shl) mice deficient in apolipoprotein E expression.
Yokota T; Nomura K; Nagashima M; Kamimura N
J Nutr Biochem; 2016 Jun; 32():46-54. PubMed ID: 27142736
[TBL] [Abstract][Full Text] [Related]
12. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice.
Lee J; Hong SW; Chae SW; Kim DH; Choi JH; Bae JC; Park SE; Rhee EJ; Park CY; Oh KW; Park SW; Kim SW; Lee WY
PLoS One; 2012; 7(2):e31394. PubMed ID: 22363635
[TBL] [Abstract][Full Text] [Related]
13. Dietary interesterified fat enriched with palmitic acid induces atherosclerosis by impairing macrophage cholesterol efflux and eliciting inflammation.
Afonso MS; Lavrador MS; Koike MK; Cintra DE; Ferreira FD; Nunes VS; Castilho G; Gioielli LA; Paula Bombo R; Catanozi S; Caldini EG; Damaceno-Rodrigues NR; Passarelli M; Nakandakare ER; Lottenberg AM
J Nutr Biochem; 2016 Jun; 32():91-100. PubMed ID: 27142741
[TBL] [Abstract][Full Text] [Related]
14. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice.
Terasaki M; Nagashima M; Nohtomi K; Kohashi K; Tomoyasu M; Sinmura K; Nogi Y; Katayama Y; Sato K; Itoh F; Watanabe T; Hirano T
PLoS One; 2013; 8(8):e70933. PubMed ID: 23967137
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis.
Liu C; Schönke M; Zhou E; Li Z; Kooijman S; Boon MR; Larsson M; Wallenius K; Dekker N; Barlind L; Peng XR; Wang Y; Rensen PCN
Cardiovasc Res; 2022 Jan; 118(2):489-502. PubMed ID: 33693480
[TBL] [Abstract][Full Text] [Related]
16. 6-mercaptopurine inhibits atherosclerosis in apolipoprotein e*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages.
Pols TW; Bonta PI; Pires NM; Otermin I; Vos M; de Vries MR; van Eijk M; Roelofsen J; Havekes LM; Quax PH; van Kuilenburg AB; de Waard V; Pannekoek H; de Vries CJ
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1591-7. PubMed ID: 20413732
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
Panjwani N; Mulvihill EE; Longuet C; Yusta B; Campbell JE; Brown TJ; Streutker C; Holland D; Cao X; Baggio LL; Drucker DJ
Endocrinology; 2013 Jan; 154(1):127-39. PubMed ID: 23183176
[TBL] [Abstract][Full Text] [Related]
18. Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress.
Yang G; Lei Y; Inoue A; Piao L; Hu L; Jiang H; Sasaki T; Wu H; Xu W; Yu C; Zhao G; Ogasawara S; Okumura K; Kuzuya M; Cheng XW
Atherosclerosis; 2017 Sep; 264():1-10. PubMed ID: 28734203
[TBL] [Abstract][Full Text] [Related]
19. Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
Kühnast S; Louwe MC; Heemskerk MM; Pieterman EJ; van Klinken JB; van den Berg SA; Smit JW; Havekes LM; Rensen PC; van der Hoorn JW; Princen HM; Jukema JW
PLoS One; 2013; 8(6):e66467. PubMed ID: 23840481
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
Ding X; Saxena NK; Lin S; Gupta NA; Anania FA
Hepatology; 2006 Jan; 43(1):173-81. PubMed ID: 16374859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
